Blood cancer dose optimization platform trial
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests different doses of blood cancer treatments to find the best balance between effectiveness and side effects. It is a platform trial, meaning it can test multiple treatments and dosages over time within the same study framework.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a blood disease, such as leukemia, lymphoma, or other disorders of the blood or bone marrow.
- You are able to join at least one of the substudies (domains) currently open in the trial.
- You are expected to live more than 3 months.
- You can understand and sign consent forms for the substudy you join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This trial tests a new drug, BL-M24D1, for people with multiple myeloma or other blood cancers that have come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
This study tests a new way to check how blood cancers respond to immunotherapy. It looks at small blood or bone marrow samples before and during treatment to help doctors choose the best therapy.
Hear when a new Waldenstrom Macroglobulinaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.